Fujifilm, Dr. Reddy’s Establish Generic JV

Fujifilm Corp. and Dr. Reddy’s Laboratories have signed a Memorandum of Understanding (MoU) to establish a joint venture to develop, manufacture and promote generic drugs in Japan. Fujifilm will hold a 51% stake and Dr. Reddy’s will have the remainder.

The JV will utilize Fujifilm’s quality control technologies and Dr. Reddy’s expertise in cost competitive production technologies for APIs and formulations. The JV plans to launch its first products in Japan in the next three to four years, and plans to design products specifically for the Japanese market.

“Shigetaka Komori, president and chief executive officer of Fujifilm Corp., said, “With the execution of the MoU with Dr. Reddy’s, Fujifilm will have excellent capability in developing and manufacturing across API and formulations of generic drugs. Through Fujifilm’s superior material process technology and quality control system, we aim to contribute to the adoption of high quality and affordable generic drugs in the Japanese market.”

GV Prasad, vice chairman and chief executive officer of Dr. Reddy’s, said, “We are very excited to partner with Fujifilm, a highly reputed Japanese company and a leading global brand, to bring world-class, high quality generic drugs to the people of Japan. We are confident that Fujifilm’s advanced R&D capabilities, quality systems and market know-how backed by Dr. Reddy’s experience as a major global generics player, will help the joint venture establish a strong presence in the Japanese pharmaceutical market.”